Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction
about
Dopamine receptor genetic polymorphisms and body composition in undernourished pastoralists: an exploration of nutrition indices among nomadic and recently settled Ariaal men of northern KenyaToward an integration of cognitive and genetic models of risk for depressionTreatment for comorbid borderline personality disorder and alcohol use disorders: a review of the evidence and future recommendationsEffects of Acute Nicotine Abstinence on Cue-elicited Ventral Striatum/Nucleus Accumbens Activation in Female Cigarette Smokers: A Functional Magnetic Resonance Imaging Study.Season of birth and dopamine receptor gene associations with impulsivity, sensation seeking and reproductive behaviors.Dopamine D4 receptor (D4R) deletion in mice does not affect operant responding for food or cocaineExposure to the taste of alcohol elicits activation of the mesocorticolimbic neurocircuitry.Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes.The incentive salience of alcohol: translating the effects of genetic variant in CNR1.Effects of nicotine deprivation and replacement on BOLD-fMRI response to smoking cues as a function of DRD4 VNTR genotype.Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes.Assortative human pair-bonding for partner ancestry and allelic variation of the dopamine receptor D4 (DRD4) gene.Do genetic and individual risk factors moderate the efficacy of motivational enhancement therapy? Drinking outcomes with an emerging adult samplePharmacogenetics of alcohol and alcohol dependence treatmentOndansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings.Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatmentDRD4 and susceptibility to peer influence on alcohol use from adolescence to adulthood.A human laboratory pilot study with baclofen in alcoholic individualsThe DRD4 exon 3 VNTR polymorphism and addiction-related phenotypes: a review.DRD4 long allele carriers show heightened attention to high-priority items relative to low-priority itemsThe dopamine D Receptor (DRD4) gene exon III polymorphism, problematic alcohol use and novelty seeking: direct and mediated genetic effects.Dose specific effects of olanzapine in the treatment of alcohol dependenceRelapse prevention for addictive behaviorsAlcoholism: the dissection for endophenotypes.Rodent versions of the iowa gambling task: opportunities and challenges for the understanding of decision-making.Examining impulsivity as an endophenotype using a behavioral approach: a DRD2 TaqI A and DRD4 48-bp VNTR association study.Effects of craving and DRD4 VNTR genotype on the relative value of alcohol: an initial human laboratory study.Blockade of dopamine d4 receptors attenuates reinstatement of extinguished nicotine-seeking behavior in rats.Associations of the dopamine D4 receptor gene VNTR polymorphism with drug use in adolescent psychiatric inpatients.Neurobiologic processes in drug reward and addiction.Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic systemInteracting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.Modulation of high alcohol drinking in the inbred Fawn-Hooded (FH/Wjd) rat strain: implications for treatment.Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment.Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.Pharmacological approaches to reducing craving in patients with alcohol use disorders.Experimental medicine in drug addiction: towards behavioral, cognitive and neurobiological biomarkers.Pharmacogenetically driven treatments for alcoholism: are we there yet?Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.
P2860
Q21283889-0B0342C7-4A80-4E6B-9BD1-3C20B0AB23A8Q26853074-3593903C-B725-4735-A633-E0E8B9E08083Q27002357-E5F44C75-426A-4753-84B4-EE0C3A712BEEQ30494499-789F7404-B412-4520-8BB3-D02EBCA625B2Q33306698-E323424F-55E5-4CC7-9410-973FA6E245F2Q33625048-8ABEFD80-DAC9-4F83-BE4C-332375667598Q33797940-6F96DAE8-BB54-41E5-A731-108F9D5C9707Q33797971-9D70FF65-FC89-4A91-91A1-65B44BE7D321Q33797978-FDAB878C-2AA0-49FA-9A1F-AA0296824364Q33813158-E94F65BC-F624-481B-864D-15E35ECA21D5Q33865218-C3A91729-F5FB-40B5-BCC7-D84F6D74EEDDQ33951301-2E163251-109A-42F9-84AE-EC0AD4748211Q34034252-F228B362-4E95-4C0E-84D8-4DE1EC9E5FDAQ34081709-4C54A06E-C33A-4EF1-A85F-069CED69DBDDQ34174792-748E193B-96E1-4C52-B68F-735915666C8AQ34311649-FF44F384-F72F-462C-8F2D-449740F9986CQ34411076-23A28796-DAC6-4CA2-BA6C-756EDD73917FQ34715407-0CE6204A-DC3E-490E-81F7-9BEDBF8518BAQ34871492-EBBC13C7-A2DC-4BCD-9362-051377D3BEE6Q34972111-27AD6568-2B1E-48BA-BAC1-3E798B4744E6Q35033588-6851D251-AC9D-4D87-9C04-E2BAA0C13046Q35151789-3CDD06DB-0A4B-4C30-A1B6-6ECF49D127C3Q35181204-5C89B4A3-F127-4237-83C5-8566BD598A26Q35184972-82921EDB-85C1-40C0-93B0-B24C5053901EQ35236604-02CFC421-B508-4287-9F5B-51AEA2D3BFB8Q35295664-18F2E462-0385-4723-BAAA-A9D91AB4BB2EQ35610068-10093126-684A-433E-BAA4-02D66C68B72AQ35651859-0E04756D-0681-49FB-8CC5-46BCCBEAE72DQ35679955-833D443D-268E-40DD-9F29-6473B659F1C1Q35781601-7F7EAB95-A265-419C-8082-E61A2F085C00Q35894612-2132E943-B0FA-4E37-A304-3093D59447EBQ35995415-8F70DFA1-5C58-4F25-A370-061202166099Q36540015-2A7E8E65-813A-4455-9B5A-45ECDF7990E3Q36589468-C56A9229-86CC-417E-B954-146B6C2569C1Q36989434-AC32D203-9FE9-479A-BDD3-25D7EF097CC0Q37344738-F8BFB8CF-DC40-470A-AFB8-63F332E822BCQ37708082-CA79AC27-C9D6-40FE-9849-439314139254Q37822217-234FD669-9E8B-479C-B74E-F1CC647C3876Q38010250-DBFCAFA0-3990-4E9D-9F48-01DE540CF947Q38718932-EAC1A05A-36E1-4428-B6F0-156A32986CBE
P2860
Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@ast
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@en
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@en-gb
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@nl
type
label
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@ast
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@en
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@en-gb
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@nl
prefLabel
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@ast
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@en
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@en-gb
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@nl
P2093
P2860
P921
P356
P1476
Olanzapine reduces craving for ...... by pharmacotherapy interaction
@en
P2093
Andrew Smolen
Angela Wooden
John McGeary
Kent E Hutchison
Lawrence Adler
Lyndee Paris
Robert M Swift
P2860
P2888
P304
P356
10.1038/SJ.NPP.1300264
P407
P577
2003-10-01T00:00:00Z
P5875
P6179
1041950542